Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis ...Middle East

-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study on ASC42 in the U.S. is expected to be completed by the beginning of the fourth quarter 2022 -- This DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more...

Hence then, the article about gannex announces first subject dosed in the u s drug drug interaction study of fxr agonist asc42 for treatment of primary biliary cholangitis was published today ( Tuesday 16/08/2022 - 03:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis )

Also on site :

• Taiwan’s economy is booming thanks to AI. Not everyone sees the benefits
• Amazon’s 2-Pack of 'Light and Airy' Tank Tops Is Just $8 and 'Perfect for Summer'
• Doing This One Thing on Vacation is Seriously Stressing Your Pets Out